The use of immunosuppressive drugs guarantees the vitality of the graft and allows gestation in spite of intercurrences such as prematurity and intrauterine growth restriction. However, little is known about the direct effects of immunosuppressive drugs on placental cells. We investigated the effects of immunosuppressive drugs in the chorionic villous explants from human term placentas of healthy gestations. Human placental explants from term gestations (37-39 week gestational age, n = 12) were exposed to cyclosporine A (CSA, 0, 62.5, 125, 1250 ng/mL) or azathioprine (AZA, 0, 5, 10, 100 ng/mL) separately or, in combination for up to 48 hours. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays showed a significant decrease in the explant metabolic activity between AZA and the control group (24 hours, 100 ng/mL, 48 hours, all concentrations, P < .005). Cyclosporin A (CsA) reduced cell activity when associated with AZA (48 hours, P < .005). Fibrinoid deposits increased in AZA-treated explants alone (5 ng/mL, 48 hours; 10 ng/mL, 24-48 hours; P < .005) or when associated with CsA (10 AZA/125 CsA, P < .05), whereas in CsA treatment alone, there was an augment in syncytial knots (24-48 hours, P < .005). The sFLT1 gene (24 hours, P < .05) and protein (P < .005) expression increased in AZA and CsA-treatments separately or in combination (P < .05). Placental growth factor increased in AZA (24 hours, 10 ng/mL) and CsA (125 ng/mL; P < .05). In conclusion, our data indicate that AZA primarily acts on the villous metabolism, perturbing placental homeostasis. Since these drugs may alter the balance of angiogenic factors in its selection for clinical application, their impact on the behavior of placental villous should be considered.
BroganPADillonMJ. The use of immunosuppressive and cytotoxic drugs in non-malignant disease. Arch Dis Child. 2000;83(3):259–264.
2.
ZandMS. Immunosuppression and immune monitoring after renal transplantation. Semin Dial. 2005;18(6):511–519.
3.
AlstonPKKullerJAMcMahonMJ. Pregnancy in transplant recipients. Obstet Gynecol Surv. 2001;56(5):289–295.
4.
JosephsonMAMckayDB. Considerations in the medical management of pregnancy in transplant recipients. Adv Chronic Kidney Dis. 2007;14(2):156–167.
5.
JosephsonMAMckayDB. Pregnancy and kidney transplantation. Semin Nephrol. 2011;31(1):100–110.
6.
OliveiraLGSassNSatoJLOsakiKSMedina-PestanaJO. Pregnancy after renal transplantation - a five-yr single-center experience. Clin Transplant. 2007;21(3):301–304.
7.
ArmentiVTConstantinescuSMoritzMJDavisonJM. Pregnancy after transplantation. Transplant Rev. 2008;22(4):223–240.
8.
SvetitskySBaruchRSchwartzIF, et al.Long-term effects of pregnancy on renal graft function in women after kidney transplantation compared with matched controls. Transplant Proc. 2018;50(5):1461–1465.
9.
ParolinMBCoelhoJCUUrbanetzAAPampuchM. Contraception and pregnancy after liver transplantation - an update overview. Arch Gastroenterol. 2009;46(2):154–158.
10.
TownsendRO’BrienPKhalilA. Current best practice in the management of hypertensive disorders in pregnancy. Integr Blood Press Control. 2016;9:79–94.
11.
SavaRIMarchKLPepineCJ. Hypertension in pregnancy: taking cues from pathophysiology for clinical practice. Clin Cardiol. 2018;41(2):220–227.
12.
BenirschkeKKaufmannPBaergenRN. Pathology of the Human Placenta. New York, NY: Springer-Verlag; 2006.
13.
Red-HorseKZhouYGenbacevO, et al.Trophoblast differentiation during embryo implantation and formation of the maternal-fetal interface. J Clin Invest. 2004;114(6):744–754.
14.
VauseSSaroyaDK. Functions of the placenta. Anaesthesia. 2005;6:77–80.
15.
ShahDAKhalilRABioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia. Biochem Pharmacol. 2015;95(4):211–226.
16.
ThellinOHeinenE. Pregnancy and the immune system: between tolerance and rejection. Toxicology. 2003;185(3):179–184.
17.
OzBBHackmanREinarsonTKorenG. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis1. Transplantation. 2001;71(8):1051–1055.
18.
JanssenNMGentaMS. the effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med. 2000;160(5):610–619.
19.
GhanemMEEl-BaghdadiLABadawyAMBakrMASobheMAGhoneimMA. Pregnancy outcome after renal allograft transplantation: 15 years experience. Eur J Obstet Gynecol Reprod Biol. 2005;121(2):178–181.
20.
DuMRZhouWHDongL, et al.Cyclosporin A promotes growth and invasiveness in vitro of human first-trimester trophoblast cells via MAPK3/MAPK1-mediated AP1 and Ca2þ/calcineurin/NFAT signalling pathways. Biol Reprod. 2008;78(6):1102–1110.
21.
HoffmannMRychlewskiJChrzanowskaMHermannT. Mechanism of activation of an immunosuppressive drug: azathioprine. Quantum chemical study on the reaction of azathioprine with cysteine. J Am Chem Soc. 2001;123(26):6404–6409.
22.
MaltzmanJSKoretzkyGA. Azathioprine: old drug, new actions. J Clin Invest. 2003;111(8):1122–1124.
23.
BerridgeMVTanAS. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys. 1993;303(2):474–482.
24.
RissTLMoravecRA. Use of multiple assay endpoints to investigate the effects of incubation time, doses of toxin, and plating density in cell-based cytotoxicity assays. Assay Drug Dev Technol. 2004;2(1):51–62.
25.
RuifrokACKatzRLJohnstonDA. Comparison of Quantification of Histochemical Staining By Hue-Saturation-Intensity (HSI) Transformation and Color-Deconvolution. Appl Immunohistochem Mol Morphol. 2003;11(1):85–91.
26.
de MattosAMOlyaeiAJBennettWM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis. 2000;35:333–346.
27.
Pacheco NetoMAlvesANLFortiniAS, et al.Therapeutic drug monitoring of azathioprine: a review. J Bras Patol Med Lab. 2008;44(3):161–167.
BoerNKHJarbandhanPGMulderCJJvan ElburgRMvan BodegravenAA. Azathioprine use during pregnancy: unexpected Intrauterine Exposure to Metabolites. Am J Gastroenterol. 2006;101(6):1390–1392.
30.
NarasimhaAVasudevaDS. Spectrum of changes in placenta in toxemia of pregnancy. Indian J Pathol Microbiol. 2011;54(1):15–20.
31.
BukowskiRHansenNIPinarH, et al.Altered fetal growth, placental abnormalities, and stillbirth. PLoS One. 2017;12(8):e0182874.
32.
FrankHGMalekzadehFKertschanskaS, et al.Immunohistochemistry of two different types of placental fibrinoid. Acta Anat. 1994;150(1):55–68.
33.
KaufmannPHuppertzBFrankHG. The fibrinoids of the human placenta: origin, composition and functional relevance. Ann Anat. 1996;178(6):485–501.
34.
BhattacharjeePBhattacharyyaD. An enzyme from Aristolochia indica destabilizes fibrin-β amyloid co-aggregate: implication in cerebrovascular diseases. PLoS One. 2015;10(11):e0141986.
35.
MayhewTM. Fetoplacental angiogenesis during gestation is biphasic, longitudinal and occurs by proliferation and remodelling of vascular endothelial cells. Placenta. 2002;23(10):742–750.
36.
ShibuyaM.Vascular endotelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem. 2013;153(1):13–19.
37.
MaynardSEMinJYMerchanJ, et al.Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649–658.
38.
VerlohrenSStepanHDechendR. Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. Clin Sci (Lond). 2012;122(2):43–52.
39.
FeskSDraegerRPeterHHEichmannKRaoA. The duration of nuclear residence of NFAT determines the pattern of cytokine expression in human SCID T cells. J Immunol. 2000;165(1):297–305.
40.
YeLGrattonAHannanNJ, et al.Nuclear factor of activated T-cells (NFAT) regulates soluble fms-like tyrosine kinase-1 secretion (sFlt-1) from human placenta. Placenta. 2016;48:110–118.
41.
WangSCTangChLPiaoHL, et al.Cyclosporine A promotes in vitro migration of human first-trimester trophoblasts via MAPK/ERK1/2-mediated NF-κB and Ca2+/calcineurin/NFAT signaling. Placenta. 2013;34(4):374–380.
42.
DuMRDongLZhouWH, et al.Cyclosporine A induces titin expression via MAPK/ERK signalling and improves proliferative and invasive potential of human trophoblast cells. Hum Reprod. 2007;22(9):2528–2537.
43.
YuNLiangYZhuHMoHPeiH. CsA Promotes XIST Expression to Regulate Human Trophoblast Cells Proliferation and Invasion Through miR-144/Titin Axis. J Cell Biochem. 2017;118(8):2208–2218.
44.
CollaLDienaDRossettiMManzioneAMMarozioLBenedettoCBianconeL. Immunosuppression in pregnant women with renal disease: review of the latest evidence in the biologics era. J Nephrol. 2018;31(3):361–383.
45.
BerganSBentdalOSodalGBrunARugstadHEStokkeO. Patterns of azathioprine metabolites in neutrophils, lymphocytes, reticulocytes, and erythrocytes: relevance to toxicity and monitoring in recipients of renal allografts. Ther Drug Monit. 1997;19(5):502–509.
46.
EklundBIGunnarsdottirSElfarraAAMannervikB. Human glutathione transferases catalyzing the bioactivation of anticancer thiopurine prodrugs. Biochem Pharmacol. 2007;73(11):1829–1841.
47.
NorgårdBPedersenLChristensenLASØrensenHT. Therapeutic drug use in women with Chron’s disease and birth outcomes. A Danish nationwide cohort study. Am J Gastroenterol. 2007;102(7):1406–1413.
48.
PlatzekTSchwabeRRahmUBochertG. DNA modification induced by 6-mercaptopurine riboside in murine embryos. Chem Biol Interact. 1994;93(1):59–71.
49.
ChaabaneWAppellML. Interconnections between apoptotic and autophagic pathways during thiopurine-induced toxicity in cancer cells: the role of reactive oxygen species. Oncotarget. 2016;7(46):75616–75634.
50.
LeeAUFarrellGC. Mechanism of azathioprine-induced injury to hepatocytes: roles of glutathione depletion and mitochondrial injury. J Hepatol. 2001;35(6):756–764.
51.
MatalonSTOrnoyAFishmanADruckerLLishnerM. The effect of 6-mercaptopurine on early human placental explants. Human Reprod. 2005;20(5):1390–1397.
52.
MalhotraSSGuptaSK. Relevance of the NR4A sub-family of nuclear orphan receptors in trophoblastic BeWo cell differentiation. Cell Mol Biol Lett. 2017;22:15.
53.
OrdentlichPYanYZhouSHeymanRA. Identification of the Antineoplastic Agent 6-Mercaptopurine as an Activator of the Orphan Nuclear Hormone Receptor Nurr1. J Biol Chem. 2003;278(27):24791–24799.
54.
BertolinKBellefleurAMZhangCMurphyBD. Orphan nuclear receptor regulation of reproduction. Anim Reprod. 2010;7(3):146–153.
